Description: Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Home Page: akerotx.com
601 Gateway Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 487 6488
Officers
| Name | Title |
|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | President, CEO & Director |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive VP, COO & Secretary |
| Dr. Timothy Rolph Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. William R. White J.D. | Executive VP, CFO, Treasurer & Head of Corporate Development |
| Ms. Catriona Yale | Executive VP & Chief Development Officer |
| Mr. Scott A. Gangloff | Chief Technical Officer |
| Mr. John J. Schembri | Senior VP & Head of Finance |
| Mr. Patrick Lamy | Senior Vice President of Commercial Strategy |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.795 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 60 |